CPC A61K 31/702 (2013.01) [A23C 9/206 (2013.01); A23L 33/21 (2016.08); A61K 31/7004 (2013.01); A61K 31/7012 (2013.01); A61P 1/04 (2018.01); A23V 2002/00 (2013.01)] | 19 Claims |
1. A method comprising:
selecting a non-infant human patient with irritable bowel syndrome (IBS) experiencing one or more IBS symptoms;
selecting an amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient; and
increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient and reducing the likelihood of the non-infant human patient experiencing the one or more IBS symptoms by administering a daily dose of the selected amount of the one or more neutral HMOs to the non-infant human patient, wherein the daily dose is from about 2.5 g to about 10 g.
|